Pharmaceutical Contract Development and Manufacturing Market

Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) - Global Forecast to 2024

Report Code: PH 7263 Jul, 2019, by marketsandmarkets.com

[186 Pages Report] The global pharmaceutical contract development and manufacturing market is projected to reach USD 126.6 billion by 2024 from USD 90.0 billion in 2019, at a CAGR of 7.1%. Growth in this market is driven by the rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs.

Pharmaceutical Contract Development and Manufacturing Market

The pharmaceutical manufacturing segment is expected to account for the largest share of the pharmaceutical contract development and manufacturing market in 2019

Pharmaceutical manufacturing services are expected to be the largest revenue contributor to the market in 2019. The large share of this segment can be attributed to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity.

Parenteral/Injectable manufacturing services are expected to grow at a high CAGR

The pharmaceutical FDF manufacturing services market, by type, includes parenteral/injectable, tablet, capsule, oral liquid, and other formulation manufacturing services. Parenteral/injectable manufacturing services are expected to grow at the highest CAGR during the forecast period due to factors such as the increasing need for high levels of expertise, increasing number of sterile formulations, and growing drug development activity.

The big pharma end-user segment is expected to account for the largest share of the pharmaceutical contract development and manufacturing market in 2019

The big pharma end user segment accounted for the largest share of the market in 2019. This is attributed to the emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets.

Pharmaceutical Contract Development and Manufacturing Market

The Asia Pacific region is expected to grow at the highest rate in the pharmaceutical contract development and manufacturing market in 2019

The market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. This is due to its growing manufacturing sector, favorable government regulations, increasing emphasis on off-patent drugs, and highly skilled workforce, all of which are driving outsourcing of pharmaceutical contract development and manufacturing to the Asia Pacific.

Key Market Players

The prominent players in the market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).

Thermo Fisher Scientific (US)

Thermo Fisher Scientific is the leading player operating in the market. It has a wide geographic footprint serving over 400,000 pharmaceutical and biotech customers. The firm clocked more than USD 3 billion in revenue in 2018 from its contract development and manufacturing business. Its extensive R&D activities have enabled it to increase its capabilities in technologies, software, and services.

Lonza Group Ltd (Switzerland)

Lonza is a provider of integrated solutions for its pharma and consumer healthcare & nutrition customers across the healthcare continuum. It is a leading player in the contract development and manufacturing market and has supported the development and manufacture of more than 800 therapies in 2017. The company focuses on enhancing its core capabilities such as manufacturing and quality control systems, regulatory expertise, technical-customer support, and R&D capabilities through organic and inorganic growth strategies.

Scope of the Report:

Report Metric

Details

Market size available for years

2017–2024

Base year considered

2018

Forecast period

2019–2024

Forecast units

Value (USD)

Segments covered

Service, End User, and Region

Geographies covered

North America, Europe, APAC, Latin America, and the Middle East & Africa

Companies covered

Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany)

The research report categorizes the market into the following segments and subsegments:

Pharmaceutical Contract Development and Manufacturing Market, by Service

  • Pharmaceutical Manufacturing Services
    • Pharmaceutical API Manufacturing
    • Pharmaceutical FDF Manufacturing
      • Parenteral/Injectable
      • Tablet
      • Capsule
      • Oral Liquid
      • Other Formulations
  • Biologics Manufacturing Services
    • Biologics API Manufacturing
    • Biologics FDF Manufacturing
  • Drug Development Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

  • Big Pharma
  • Small & Mid-size Pharma
  • Generic Pharmaceutical Companies
  • Other End Users

Pharmaceutical Contract Development and Manufacturing Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of APAC
  • Latin America
  • Middle East and Africa

Recent Developments

  • In 2019, Lonza Group launched its CellBio Services.
  • In 2019, Thermo Fisher invested USD 150 million in its Pharma Services business segment to expand its manufacturing capacity for sterile liquid and lyophilized product development and commercial manufacturing.
  • In 2019, Catalent launched OneBio Suite.
  • In 2018, Lonza expanded its Drug Product Services (DPS).

Critical questions the report answers:

  • Where will all these developments take the industry in the medium to long-term?
  • Which are the major types of services offered in pharmaceutical contract development and manufacturing?
  • Which geographies are likely to grow at the highest CAGR?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 18)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 21)
    2.1 Research Approach
           2.1.1 Secondary Research
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Research
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Breakdown of Primaries
                    2.1.2.3 Key Industry Insights
    2.2 Market Size Estimation
    2.3 Data Triangulation Approach
    2.4 Market Players Ranking Analysis
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 28)

4 Premium Insights (Page No. - 32)
    4.1 Pharmaceutical Contract Development and Manufacturing: Market Overview
    4.2 Pharmaceutical Contract Development and Manufacturing Market: Geographic Growth Opportunities
    4.3 Regional Mix: Market (2019–2024)
    4.4 Market: Developed vs. Developing Markets, 2019 vs. 2024

5 Market Overview (Page No. - 36)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growing Demand for Generics
                    5.2.1.2 Increasing Investments in Pharmaceutical R&D
                    5.2.1.3 Investments in Advanced Manufacturing Technologies By Cdmos
           5.2.2 Opportunities
                    5.2.2.1 Increasing Demand for Biological therapies
                    5.2.2.2 Growing Focus on Specialty Medicines
                    5.2.2.3 Growth in the Nuclear Medicine Sector
                    5.2.2.4 Growing Demand for Cell and Gene therapies
           5.2.3 Challenges
                    5.2.3.1 Introduction of Serialization
                    5.2.3.2 Changing Trade Policies Between Countries
           5.2.4 Trends
                    5.2.4.1 Increasing Cdmo Manufacturing Footprint in Asian Countries
                    5.2.4.2 Cdmo Industry Consolidation
                    5.2.4.3 Increasing Outsourcing of Clinical Trials to Emerging Markets

6 Pharmaceutical Contract Development and Manufacturing Market, By Service (Page No. - 46)
    6.1 Introduction
    6.2 Pharmaceutical Manufacturing Services
           6.2.1 Pharmaceutical Api Manufacturing Services
                    6.2.1.1 Need to Cut Costs and Ensure Focus on Core Areas Leads Companies to Outsource Api Manufacturing
           6.2.2 Pharmaceutical FDF Manufacturing Services
                    6.2.2.1 Parenteral/Injectable Manufacturing Services
                               6.2.2.1.1 Need for High Levels of Expertise and Growing Drug Development Activity are Driving the Demand for Contract Manufacturing
                    6.2.2.2 Tablet Manufacturing Services
                               6.2.2.2.1 Shifting Manufacturing Requirements and Need to Streamline Production Processes Is Driving Market Growth
                    6.2.2.3 Capsule Manufacturing Services
                               6.2.2.3.1 Growth in Demand for Capsule Formulations has Ensured Growth Opportunities for Service Providers
                    6.2.2.4 Oral Liquid Manufacturing Services
                               6.2.2.4.1 Complexities Involved in Oral Liquid Manufacturing Have Prompted Companies to Look to Outsourcing
                    6.2.2.5 Other Formulations
    6.3 Drug Development Services
           6.3.1 Drug Substance Complexity and High Costs Have Supported the Outsourcing of Drug Development
    6.4 Biologics Manufacturing Services
           6.4.1 Biologics Api Manufacturing Services
                    6.4.1.1 The Market for Biologics Api Manufacturing Is Still in the Emergent Phase
           6.4.2 Biologics FDF Manufacturing Services
                    6.4.2.1 Increasing R&D Costs and Process Complexity Have Prompted the Shift Toward Contract Manufacturing

7 Pharmaceutical Contract Development and Manufacturing Market, By End User (Page No. - 68)
    7.1 Introduction
    7.2 Big Pharma
           7.2.1 Emergence of New Medicines and therapy Forms to Contribute to the Growth of This Market
    7.3 Small & Mid-Size Pharma
           7.3.1 Growing Development of Biologic Drugs and High Pricing Pressure to Boost Market Growth
    7.4 Generic Pharmaceutical Companies
           7.4.1 Growing Demand for Generics to Support Market Growth
    7.5 Other End Users

8 Pharmaceutical Contract Development and Manufacturing Market, By Region (Page No. - 76)
    8.1 Introduction
    8.2 Europe
           8.2.1 Italy
                    8.2.1.1 Increasing Focus on Clinical Research and the Growing Popularity of Branded Drugs are Driving the Demand for Contract Development and Manufacturing
           8.2.2 Germany
                    8.2.2.1 High Healthcare Expenditure and Increased Pharmaceutical Production to Support Market Growth
           8.2.3 France
                    8.2.3.1 Presence of Leading Pharmaceutical Companies to Support Market Growth in France
           8.2.4 UK
                    8.2.4.1 Growth in the Generics Market and the Rising Cost of Manufacturing Parenteral Formulations are Driving Market Growth
           8.2.5 Switzerland
                    8.2.5.1 Large Volume of Pharmaceutical Production and Growing Scope for Generics Is Expected to Growth Opportunities
           8.2.6 Spain
                    8.2.6.1 Increase in Biologics Production to Support Market Growth
           8.2.7 Rest of Europe
    8.3 North America
           8.3.1 US
                    8.3.1.1 The US Dominates the North American Market
           8.3.2 Canada
                    8.3.2.1 Growth of the Emerging Markets and Slowdown in New Product Approvals Will Hamper Market Growth
    8.4 Asia Pacific
           8.4.1 India
                    8.4.1.1 Low Manufacturing Costs and A Skilled Workforce are Factors Attracting Outsourcing and Investment to India
           8.4.2 China
                    8.4.2.1 Favorable Government Regulations are Fueling Market Growth in China
           8.4.3 Japan
                    8.4.3.1 Growing Generics Demand and Push From the Government Will Drive the Demand for Contract Manufacturing of Drugs
           8.4.4 Rest of Asia Pacific
    8.5 Latin America
           8.5.1 Favorable Cost Structure and Government Investments to Drive Pharmaceutical Production in Latam
    8.6 Middle East & Africa
           8.6.1 Government Support to Boost Local Production Is Expected to Offer Growth Opportunities for the Contract Manufacturers in the Region

9 Competitive Landscape (Page No. - 132)
    9.1 Overview
    9.2 Market Ranking
           9.2.1 Pharmaceutical Contract Development and Manufacturing Market, By Key Players, 2018
    9.3 Competitive Leadership Mapping
           9.3.1 Visionary Leaders
           9.3.2 Innovators
           9.3.3 Dynamic Differentiators
           9.3.4 Emerging Companies
    9.4 Competitive Situation and Trends
           9.4.1 Product Launches
           9.4.2 Expansions
           9.4.3 Acquisitions
           9.4.4 Agreements, Partnerships, and Collaborations

10 Company Profiles (Page No. - 142)
(Business Overview, Products Offered, Recent Developments, MnM View)* 
     10.1 Thermo Fisher Scientific Inc.
     10.2 Catalent, Inc.
     10.3 Lonza Group Ltd
     10.4 Recipharm AB
     10.5 Vetter Pharma International GmbH
     10.6 Famar Health Care Services
     10.7 Abbvie Inc.
     10.8 Aenova Group
     10.9 Consort Medical Plc
     10.10 Almac Group
     10.11 Siegfried Holding AG
     10.12 Evonik Industries AG
     10.13 Boehringer Ingelheim International GmbH
*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies. 

11 Appendix (Page No. - 179)
     11.1 Insights of Industry Experts
     11.2 Discussion Guide
     11.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     11.4 Available Customizations
     11.5 Related Reports
     11.6 Author Details


List of Tables (119 Tables)

Table 1 Market, By Service, 2017–2024 (USD Million)
Table 2 Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 3 Pharmaceutical Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 4 Pharmaceutical Api Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 5 Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 6 Pharmaceutical FDF Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 7 Parenteral/Injectable Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 8 Tablet Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 9 Capsule Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 10 Oral Liquid Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 11 Other Formulation Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 12 Drug Development Services Market, By Country, 2017–2024 (USD Million)
Table 13 Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 14 Biologics Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 15 Biologics Api Manufacturing Services Market, By Country, 2017–2024 (USD Million)
Table 16 Biologics Finished Dosage Formulations Market, By Country, 2017–2024 (USD Million)
Table 17 Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 18 Market for Big Pharma, By Country, 2017–2024 (USD Million)
Table 19 Market for Small & Mid-Size Pharma, By Country, 2017–2024 (USD Million)
Table 20 Market for Generic Pharmaceutical Companies, By Country, 2017–2024 (USD Million)
Table 21 Market for Other End Users, By Country, 2017–2024 (USD Million)
Table 22 Market, By Region, 2017–2024 (USD Million)
Table 23 Europe: Market, By Country, 2017–2024 (USD Million)
Table 24 Europe: Pharmaceutical Contract Development and Manufacturing Market, By Service, 2017–2024 (USD Million)
Table 25 Europe: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 26 Europe: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 27 Europe: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 28 Europe: Market, By End User, 2017–2024 (USD Million)
Table 29 Italy: Market, By Service, 2017–2024 (USD Million)
Table 30 Italy: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 31 Italy: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 32 Italy: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 33 Italy: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 34 Germany: Market, By Service, 2017–2024 (USD Million)
Table 35 Germany: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 36 Germany: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 37 Germany: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 38 Germany: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 39 France: Market, By Service, 2017–2024 (USD Million)
Table 40 France: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 41 France: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 42 France: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 43 France: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 44 UK: Market, By Service, 2017–2024 (USD Million)
Table 45 UK: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 46 UK: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 47 UK: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 48 UK: Market, By End User, 2017–2024 (USD Million)
Table 49 Switzerland: Market, By Service, 2017–2024 (USD Million)
Table 50 Switzerland: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 51 Switzerland: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 52 Switzerland: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 53 Switzerland: Market, By End User, 2017–2024 (USD Million)
Table 54 Spain: Market, By Service, 2017–2024 (USD Million)
Table 55 Spain: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 56 Spain: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 57 Spain: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 58 Spain: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 59 RoE: Market, By Service, 2017–2024 (USD Million)
Table 60 RoE: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 61 RoE: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 62 RoE: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 63 RoE: Market, By End User, 2017–2024 (USD Million)
Table 64 North America: Market, By Country, 2017–2024 (USD Million)
Table 65 North America: Market, By Service, 2017–2024 (USD Million)
Table 66 North America: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 67 North America: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 68 North America: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 69 North America: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 70 US: Market, By Service, 2017–2024 (USD Million)
Table 71 US: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 72 US: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 73 US: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 74 US: Market, By End User, 2017–2024 (USD Million)
Table 75 Canada: Market, By Service, 2017–2024 (USD Million)
Table 76 Canada: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 77 Canada: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 78 Canada: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 79 Canada: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 80 Asia Pacific: Market, By Country, 2017–2024 (USD Million)
Table 81 Asia Pacific: Market, By Service, 2017–2024 (USD Million)
Table 82 Asia Pacific: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 83 Asia Pacific: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 84 Asia Pacific: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 85 Asia Pacific: Market, By End User, 2017–2024 (USD Million)
Table 86 India: Market, By Service, 2017–2024 (USD Million)
Table 87 India: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 88 India: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 89 India: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 90 India: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 91 China: Market, By Service, 2017–2024 (USD Million)
Table 92 China: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 93 China: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 94 China: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 95 China: Market, By End User, 2017–2024 (USD Million)
Table 96 Japan: Market, By Service, 2017–2024 (USD Million)
Table 97 Japan: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 98 Japan: FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 99 Japan: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 100 Japan: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 101 RoAPAC: Market, By Service, 2017–2024 (USD Million)
Table 102 RoAPAC: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 103 RoAPAC: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 104 RoAPAC: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 105 RoAPAC: Pharmaceutical Contract Development and Manufacturing Market, By End User, 2017–2024 (USD Million)
Table 106 Latin America: Market, By Service, 2017–2024 (USD Million)
Table 107 Latin America: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 108 Latin America: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 109 Latin America: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 110 Latin America: Market, By End User, 2017–2024 (USD Million)
Table 111 Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market, By Service, 2017–2024 (USD Million)
Table 112 Middle East & Africa: Pharmaceutical Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 113 Middle East & Africa: Pharmaceutical FDF Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 114 Middle East & Africa: Biologics Manufacturing Services Market, By Type, 2017–2024 (USD Million)
Table 115 Middle East & Africa: Market, By End User, 2017–2024 (USD Million)
Table 116 Product Launches, 2016–2019
Table 117 Expansions, 2016–2019
Table 118 Acquisitions, 2016–2019
Table 119 Agreements, Partnerships, and Collaborations 2016–2019


List of Figures (37 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designations, and Region
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Pharmaceutical Contract Development and Manufacturing Market, By Service, 2019 vs. 2024 (USD Billion)
Figure 7 Biologics Manufacturing Services Market, By Type, 2019 vs. 2024 (USD Billion)
Figure 8 Market, By End User, 2019 vs. 2024 (USD Billion)
Figure 9 Geographical Snapshot of the Pharmaceutical Contract Development and Manufacturing Market
Figure 10 Growing Demand for Generics Is One of the Key Factors Driving Market Growth
Figure 11 India Is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 12 Asia Pacific to Grow at the Highest Rate During the Forecast Period (2019–2024)
Figure 13 Developing Markets to Register A Higher Growth Rate Between 2019 & 2024
Figure 14 Market: Drivers, Opportunities, Challenges, and Trends
Figure 15 Growth of the Generics Market (2006 vs. 2016)
Figure 16 Number of Pharma Companies With Active Drug Pipeline Projects (2010–2017)
Figure 17 Global Life Science R&D Spending (2016–2018)
Figure 18 Cdmo Merger and Acquisition Volume and Value (2012–2016)
Figure 19 Top Consolidators (2012–2018)
Figure 20 Pharmaceutical Manufacturing Services Segment to Dominate the Services Market During the Forecast Period
Figure 21 Big Pharma Formed the Largest End User Segment in the Pharmaceutical Contract Development and Manufacturing Market
Figure 22 Market: Geographical Snapshot
Figure 23 Europe: Market Snapshot
Figure 24 North America: Market Snapshot
Figure 25 Asia Pacific: Market Snapshot
Figure 26 Key Growth Strategies Adopted By Market Players From January 2016 to July 2019
Figure 27 Pharmaceutical Contract Development and Manufacturing Market Ranking, By Key Player, 2018
Figure 28 Market: (Global) Competitive Leadership Mapping (2018)
Figure 29 Thermo Fisher Scientific Inc.: Company Snapshot (2018)
Figure 30 Catalent, Inc.: Company Snapshot (2018)
Figure 31 Lonza Group Ltd: Company Snapshot (2018)
Figure 32 Recipharm AB: Company Snapshot (2018)
Figure 33 Abbvie Inc.: Company Snapshot (2018)
Figure 34 Consort Medical Plc: Company Snapshot (2018)
Figure 35 Siegfried Holding AG: Company Snapshot (2018)
Figure 36 Evonik Industries AG: Company Snapshot (2018)
Figure 37 Boehringer Ingelheim International GmbH: Company Snapshot (2018)

In this report, the global market for pharmaceutical contract development and manufacturing was arrived at after the assessment of major service segments and their shares in the overall market. For this purpose, the share of major service segments was determined through various insights gathered during primary and secondary research. The research process involved the study of various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of widespread secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and company house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global pharmaceutical contract development and manufacturing market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, manufacturing managers, and related key executives from various key companies and organizations operating in the global market. The primary sources from the demand side include purchase and sales managers, research organizations, and pharmaceutical and biotechnology companies.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and market dynamics. A breakdown of the primary respondents is provided below:

Pharmaceutical Contract Development and Manufacturing Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by service, end user, and region).

Data Triangulation

After arriving at the market size, the total pharmaceutical contract development and manufacturing market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, and forecast the market by service, end user, and region
  • To provide detailed information about the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies in the market
  • To track and analyze competitive developments such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, and geographical expansions in the pharmaceutical contract manufacturing market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • A further breakdown of the Latin American pharmaceutical contract development and manufacturing market into Brazil, Mexico, and other countries
Report Code
PH 7263
Published ON
Jul, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Development and Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home